Bank of New York Mellon
ACET icon

Bank of New York Mellon’s Adicet Bio ACET Stock Holding History

Bank of New York Mellon’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,128
Closed -$343K – 4121
2024
Q1 		$343K Buy
9,128
+3,032
+50% +$125K ﹤0.01% 3719
2023
Q4 		$184K Sell
6,096
-2,116
-26% -$46.1K ﹤0.01% 3973
2023
Q3 		$180K Buy
8,212
+1,908
+30% +$67.4K ﹤0.01% 3991
2023
Q2 		$245K Buy
6,304
+51
+0.8% +$4.5K ﹤0.01% 3914
2023
Q1 		$576K Buy
6,253
+22
+0.4% +$2.76K ﹤0.01% 3423
2022
Q4 		$891K Sell
6,231
-2,175
-26% -$543K ﹤0.01% 3249
2022
Q3 		$1.91M Buy
8,406
+1,217
+17% +$309K ﹤0.01% 2884
2022
Q2 		$1.68M Sell
7,189
-442
-6% -$97.1K ﹤0.01% 2935
2022
Q1 		$2.44M Buy
7,631
+925
+14% +$213K ﹤0.01% 2824
2021
Q4 		$1.88M Buy
6,706
+819
+14% +$141K ﹤0.01% 3031
2021
Q3 		$737K Buy
5,887
+450
+8% +$55.8K ﹤0.01% 3581
2021
Q2 		$895K Buy
5,437
+2,762
+103% +$563K ﹤0.01% 3489
2021
Q1 		$560K Sell
2,675
-3
-0.1% -$689 ﹤0.01% 3625
2020
Q4 		$602K Buy
2,678
+637
+31% +$130K ﹤0.01% 3522
2020
Q3 		$388K Buy
2,041
+1,677
+461% +$424K ﹤0.01% 3609
2020
Q2 		$88K Sell
364
-353
-49% -$69.4K ﹤0.01% 3920
2020
Q1 		$83K Buy
717
+257
+56% +$38.1K ﹤0.01% 3886
2019
Q4 		$77K Buy
460
+3
+0.7% +$1.52K ﹤0.01% 4054
2019
Q3 		$452K Buy
457
+52
+13% +$58.1K ﹤0.01% 3586
2019
Q2 		$464K Buy
405
+143
+55% +$130K ﹤0.01% 3639
2019
Q1 		$201K Buy
262
+14
+6% +$12.7K ﹤0.01% 3891
2018
Q4 		$239K Buy
248
+22
+10% +$29K ﹤0.01% 3788
2018
Q3 		$383K Buy
226
+32
+16% +$41.7K ﹤0.01% 3752
2018
Q2 		$199K Buy
194
+84
+76% +$90.4K ﹤0.01% 3923
2018
Q1 		$118K Buy
+110
New +$202K ﹤0.01% 4027

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Bank of New York Mellon's ACET Position: Q2 2024 in Review

Bank of New York Mellon sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 9,128 shares — an estimated $343K sold.

Bank of New York Mellon first reported a position in ACET in Q1 2018 and held it in 25 quarters. The position peaked at $2.44M in Q1 2022. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

  • Bank of New York Mellon reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 9,128 Adicet Bio shares in Q2 2024, an estimated $343K.
  • Bank of New York Mellon first reported a position in Adicet Bio in Q1 2018 and held it in 25 quarters.
  • Bank of New York Mellon's Adicet Bio position peaked at $2.44M in Q1 2022.
  • 86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.